Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended		170 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2013 MultiGen Diagnostics, Inc.
Operating activities
Net loss	$ (10,782,018)	$ (5,239,275)	$ (64,390,151)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense	2,085		2,085
Depreciation and amortization	85,532	26,331	345,173
Stock based compensation expense	1,856,684	349,010	13,869,149
Founders', compensation contributed to equity			1,655,031
Donated services contributed to equity			829,381
Settlement of consulting services in stock			478,890
Amortization of deferred debt costs and original issue discount			2,346,330
Liquidated damages and other forbearance agreement settlement costs paid in stock			1,758,111
Interest expense on convertible debentures paid in stock			757,198
Change in fair value of financial instruments	2,933,527	1,824,565	8,428,326
Gain on extinguishment of debt			(623,383)
Purchased in process research and development expense-related party			2,666,869
Stock issued in connection with payment of deferred salary			28,346
Stock issued in connection with settlement of legal fees			100,000
Stock and warrant issued in connection with consulting services		164,889	452,389
Changes in operating assets and liabilities:
Increase in other assets	(49,831)		(119,712)
Decrease (increase) in accounts receivable	98,815	(29,048)	(69,567)
Increase in prepaid expenses	(69,352)	(14,594)	(129,393)
Increase (decrease) in accounts payable, accrued expenses and other	462,078	(701,019)	1,140,697
Net cash used in operating activities	(5,462,480)	(3,619,141)	(30,474,231)
Investing activities:
Assets acquired in Etherogen, Inc. merger			(104,700)
Capital expenditures	(571,097)	(212,220)	(1,085,480)
Net cash used in investing activities	(571,097)	(212,220)	(1,190,180)
Financing activities
Proceeds from sale of 6% convertible debenture			2,335,050
Debt issuance costs			(297,104)
Proceeds from sale of common stock, net of expenses	18,897,388	10,946,115	51,652,940
Proceeds from exercise of warrants	3,599,831		3,599,830
Proceeds from exercise of options			600
Proceeds from a non-exclusive selling agent's agreement			142,187
Borrowings under capital lease line	515,964		515,964
Costs associated with recapitalization			(362,849)
Proceeds from sale of preferred stock			2,771,000
Payment of finders' fee on preferred stock			(277,102)
Redemption of common stock			(500,000)
Payment of preferred stock dividends			(116,718)
Net cash provided by financing activities	23,013,183	10,946,115	59,463,798
Net change in cash and equivalent	16,979,606	7,114,754	27,799,387
Cash and cash equivalents-Beginning of period	10,819,781	700,374
Cash and cash equivalents-End of period	27,799,387	7,815,128	27,799,387
Supplementary disclosure of cash flow activity:
Cash paid for taxes	7,650		7,650
Cash paid for interest	3,339		3,339
Supplemental disclosure of non-cash investing and financing activities:
Issuance of common stock pursuant to acquisitions				187,500
Reclassification of derivative financial instruments to additional paid in capital	(5,417,871)	(3,317,463)	(8,735,334)
Correction of error in derivative financial instruments		(274,967)	(274,967)
Issuance of 41,750 shares of common stock for Board of Directors' fees in lieu of cash payment			125,250
Conversion of $2,335,050 of 6% debentures			1,130,164
Series A Preferred beneficial conversion feature accreted as a dividend			455,385
Preferred stock dividends accrued	20,630	28,680	217,715
Interest paid on common stock			$ 1,325,372